Direct answer: Shawn Johnson East's October 2023 interview about body image and her experience in gymnastics does not identify Ozempic use or an Ozempic denial. The earlier article combined that account with a proposed clinical explanation of her medication choices. The interview does not provide the treatment history needed for that conclusion.
What the original interview actually covers
The published transcript of her October 12, 2023 interview includes her own account of pressure around appearance in competitive gymnastics. She discusses how outside judgments affected her and the support she found afterward. These statements provide context for her experience; they do not name a current weight-management prescription.
| Source material | What it establishes | What it cannot determine |
|---|---|---|
| Johnson East's account of appearance pressure | Her own description of that experience. | Her current medication list. |
| Her discussion of support and recovery | The support she discussed in this interview. | A present treatment decision or its clinical rationale. |
| The interview's publication date | When this account was published. | Whether a treatment changed later. |
A public history is not an individual prescribing decision
The old article used her past body-image experiences to characterize potential medication use as a relative contraindication. It did not cite a treatment assessment for her. General discussion about a drug cannot establish what a named person's clinician considered, recommended or prescribed.
It also compared her with another athlete's disclosure. One person's named prescription does not supply another person's medication history, even when their public careers share features. Likewise, an athletic background supplies no current measured body composition or eligibility assessment.
The corrected answer is limited to the reviewed interview. It does not present an exhaustive search of every statement Johnson East may have made, and it does not turn an absent drug name into a categorical “never.”
FAQ: Questions about the available record
Does this interview confirm Ozempic use?
No. It does not identify Ozempic as her treatment.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Does it contain a verified Ozempic denial?
No denial is established by the cited interview.
Can another athlete's treatment identify hers?
No. Each disclosure belongs to the person who made it.
Original source
Footer disclaimers
FormBlends Role. FormBlends is a digital health platform that connects patients with independent licensed clinicians and U.S.-based compounding pharmacies. We do not write prescriptions or make clinical decisions. Prescribing belongs to the clinician.
Compounded Medications. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by state-licensed 503A compounding pharmacies based on a prescription written for a specific patient. They have not been reviewed by the FDA for safety, efficacy, or manufacturing consistency and are not interchangeable with brand-name products.
Individual Variation. Trial averages do not predict any individual's results. Outcomes vary with adherence, comorbidities, prior weight history, lactation status, eating disorder history, and other factors. Statements about average outcomes reference published clinical trial data.
Trademark and Affiliation Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Shawn Johnson East's name, image, and personal brand are her own property. FormBlends has no affiliation with, sponsorship from, or endorsement by Shawn Johnson East, Andrew East, or any related entities.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →